Hongying Wang, PhD, MD
MD 1995 Zhejiang University Medical School
PhD (Pharmacology) 2000 University of Hong Kong
Investigator
State Key Laboratory of
Molecular Oncology
Cancer Institute and Hospital
Chinese Academy of Medical Sciences
No. 17 Panjiayuan,
Chaoyang District
P.O. Box 2258,
Beijing 100021
P. R. China
Research
|
Colon cancer is the third leading cancer in the whole world. Inflammatory
Bowel Disease (IBD), a chronic inflammation, not only increases the
incidence but also promotes the growth of colon cancer. We are investigating
how inflammation and tumor microenvironment affect tumor cell behaviors
including the expression of oncogenes, proliferation and apoptosis. At
present, the inflammatory mediators we study on are nitric oxide (NO),
proteinase activated receptors (PARs) and Toll like receptors (TLRs). We
mainly focus on the cell signaling and molecular mechanism by which
inflammatory mediators regulate tumorigenesis. Moreover, we are interested
in the role of Wnt/beta-catenin pathway in the interaction of epithelial
cells and microenvironment and also how inflammation affects the regulation
of stem cell and progenitor cell in gut. The long term goal of our study is
looking for new strategies of prevention, early diagnosis and treatment for
colon cancer, especially colitis-related colon cancer. |
| View PubMed Listings for Hongying Wang |
| View PubMed Listings for Hongying Wang |
| View PubMed Listings for Hongying Wang |